Evidence map›Paper›PMID 37249603›Full record

ArticleCancer research2023

Oncogenic Transformation Drives DNA Methylation Loss and Transcriptional Activation at Transposable Element Loci.

Tomas Kanholm, Uzma Rentia, Melissa Hadley, Jennifer A Karlow, Olivia L Cox, Noor Diab, Matthew L Bendall, Tyson Dawson, James I McDonald, Wenbing Xie and 5 more

Open access · greenAbstract read
In one paragraph

Article in Cancer research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Transposons disrupt genomic stability and trigger cancers.Frontiers in cellular and infection microbiology · 2025
    Review
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 2 countries.

Tomas KanholmThe George Washington University Cancer Center (GWCC), Washington, DC.ORCID 0000-0001-6894-8875
Uzma RentiaThe George Washington University Cancer Center (GWCC), Washington, DC.ORCID 0000-0002-1538-935X
Melissa HadleyThe George Washington University Cancer Center (GWCC), Washington, DC.ORCID 0009-0000-0410-9917
Jennifer A KarlowDepartment of Pathology, Dana-Farber Cancer Institute/Harvard Medical School, Boston, Massachusetts.ORCID 0000-0001-5041-2669
Olivia L CoxThe George Washington University Cancer Center (GWCC), Washington, DC.ORCID 0000-0002-0515-1073
Noor DiabThe George Washington University Cancer Center (GWCC), Washington, DC.ORCID 0000-0003-1665-8125
Matthew L BendallDivision of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, New York.ORCID 0000-0001-9816-5425
Tyson DawsonThe Institute for Biomedical Sciences at the George Washington University, Washington, DC.ORCID 0000-0003-4888-9673
James I McDonaldThe George Washington University Cancer Center (GWCC), Washington, DC.ORCID 0000-0002-5497-0083
Wenbing XieHefei National Laboratory for Physical Sciences at the Microscale, Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.ORCID 0000-0003-2546-2415
Keith A CrandallComputational Biology Institute, Department of Biostatistics and Bioinformatics, Milken Institute School of Public Health, The George Washington University, Washington, DC.ORCID 0000-0002-0836-3389
Kathleen H BurnsDepartment of Pathology, Dana-Farber Cancer Institute/Harvard Medical School, Boston, Massachusetts.ORCID 0000-0003-1620-3761
Stephen B BaylinDepartment of Oncology, The Johns Hopkins School of Medicine, The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.ORCID 0000-0003-3697-3798
Hari EaswaranHefei National Laboratory for Physical Sciences at the Microscale, Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.ORCID 0000-0002-5517-2972
Katherine B ChiappinelliThe George Washington University Cancer Center (GWCC), Washington, DC.ORCID 0000-0001-9241-9105
George Washington University · USDana-Farber Cancer Institute · USMilken Institute · USUniversity of Science and Technology of China · CNCornell University · USJohns Hopkins University · US

Funding

TRAINING GRANT IN GENETICST32GM007748 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI Anne O'Donnell-Luria, Louise Wilkins-Haug · 1985 to 2026
$12.0M
DNA Methyltrasferase Gene Expression in Colon CancerR01ES011858 · NIEHS · JOHNS HOPKINS UNIVERSITY · PI BAYLIN, STEPHEN B., EASWARAN, HARIHARAN · 2002 to 2023
$11.5M
Regulatory Crosstalk Between Human Endogenous Retroviruses, HIV, and EBV, in LymphomaR01CA260691 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI CESARMAN, ETHEL, NIXON, DOUGLAS F · 2021 to 2025
$5.8M
Regulation of repetitive elements in cancer by P53 and epigenetic mechanismsR37CA251270 · NCI · GEORGE WASHINGTON UNIVERSITY · PI Katherine B Chiappinelli · 2021 to 2026
$2.2M
HIV induced anti-cancer HERV immunity in prostate, breast and colon cancersR01CA206488 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI NIXON, DOUGLAS F · 2016 to 2020
$2.2M
(PQ4) - Tools for simultaneous disruption of multiple epigenetically silenced genes for studying their roles in tumorigenesis using ex vivo human and mouse colon organoid and in vivo mouse modelsR01CA230995 · NCI · JOHNS HOPKINS UNIVERSITY · PI BAYLIN, STEPHEN B., EASWARAN, HARIHARAN · 2018 to 2022
$1.9M
Organoid modeling to determine and reverse age-related epigenetic changes contributing to risk of colorectal cancerR01CA229240 · NCI · JOHNS HOPKINS UNIVERSITY · PI BAYLIN, STEPHEN B., EASWARAN, HARIHARAN · 2019 to 2024
$1.9M
Cancer Biology Training Program (CBTP)T32CA247756 · NCI · GEORGE WASHINGTON UNIVERSITY · PI LEE, NORMAN H, SETO, EDWARD · 2020 to 2024
$1.4M
Expression and Impact of Interspersed RepeatsR01GM130680 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI BURNS, KATHLEEN H · 2019 to 2022
$1.4M
Epigenetic activation of the interferon response to sensitize cancers to immune therapyR00CA204592 · NCI · GEORGE WASHINGTON UNIVERSITY · PI CHIAPPINELLI, KATHERINE B · 2017 to 2019
$747k
Role of human endogenous retroviruses in tumor immunity of ovarian carcinomaR21CA227259 · NCI · GEORGE WASHINGTON UNIVERSITY · PI CHIAPPINELLI, KATHERINE B, STRICK, REINER · 2018 to 2019
$334k
Characterizing age-associated epigenetic alterations and their roles in tumor developmentU01AG066101 · NIA · JOHNS HOPKINS UNIVERSITY · PI BAYLIN, STEPHEN B., EASWARAN, HARIHARAN · 2019 to 2020
$246k
NCI NIH HHS R00 CA204592NCI NIH HHS R01 CA206488NCI NIH HHS R01 CA229240NCI NIH HHS R01 CA230995NCI NIH HHS R01 CA260691NCI NIH HHS R21 CA227259NCI NIH HHS R37 CA251270NCI NIH HHS T32 CA247756NIA NIH HHS U01 AG066101NIEHS NIH HHS R01 ES011858NIGMS NIH HHS R01 GM130680NIGMS NIH HHS T32 GM007748
6 · The paper itself

Abstract

Transposable elements (TE) are typically silenced by DNA methylation and repressive histone modifications in differentiated healthy human tissues. However, TE expression increases in a wide range of cancers and is correlated with global hypomethylation of cancer genomes. We assessed expression and DNA methylation of TEs in fibroblast cells that were serially transduced with hTERT, SV40, and HRASR24C to immortalize and then transform them, modeling the different steps of the tumorigenesis process. RNA sequencing and whole-genome bisulfite sequencing were performed at each stage of transformation. TE expression significantly increased as cells progressed through transformation, with the largest increase in expression after the final stage of transformation, consistent with data from human tumors. The upregulated TEs were dominated by endogenous retroviruses [long terminal repeats (LTR)]. Most differentially methylated regions (DMR) in all stages were hypomethylated, with the greatest hypomethylation in the final stage of transformation. A majority of the DMRs overlapped TEs from the RepeatMasker database, indicating that TEs are preferentially demethylated. Many hypomethylated TEs displayed a concordant increase in expression. Demethylation began during immortalization and continued into transformation, while upregulation of TE transcription occurred in transformation. Numerous LTR elements upregulated in the model were also identified in The Cancer Genome Atlas datasets of breast, colon, and prostate cancer. Overall, these findings indicate that TEs, specifically endogenous retroviruses, are demethylated and transcribed during transformation. SIGNIFICANCE: Analysis of epigenetic and transcriptional changes in a transformation model reveals that transposable element expression and methylation are dysregulated during oncogenic transformation.

Indexed as

DNA MethylationNeoplasmsDNA Transposable ElementsHumansSequence Analysis, RNATranscriptional ActivationDNA Transposable Elements

Identifiers

PMID37249603
PMCPMC10527578
OpenAlexW4378745946

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.